|
Q3 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Oct 1, 2019
|
Q1 FY2020
As of Jun 30, 2019
|
Q4 FY2019
As of Mar 31, 2019
|
Q3 FY2019
As of Dec 31, 2018
|
Q2 FY2019
As of Sep 30, 2018
|
Q1 FY2019
As of Jun 30, 2018
|
Q4 FY2018
As of Mar 31, 2018
|
Q3 FY2018
As of Dec 31, 2017
|
Q2 FY2018
As of Sep 30, 2017
|
Q1 FY2018
As of Jun 30, 2017
|
Q4 FY2017
As of Mar 31, 2017
|
Q3 FY2017
As of Dec 31, 2016
|
Q2 FY2017
As of Sep 30, 2016
|
Q1 FY2017
As of Jun 30, 2016
|
Q4 FY2016
As of Mar 31, 2016
|
Q3 FY2016
As of Dec 31, 2015
|
Q2 FY2016
As of Sep 30, 2015
|
Q1 FY2016
As of Jun 30, 2015
|
Q4 FY2015
As of Mar 31, 2015
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash held in trust | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaids and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Long-term right-of-use assets | ||||||||||||||||||||
| Equity investments | ||||||||||||||||||||
| Unamortization balance of intangible asset | ||||||||||||||||||||
| Deposit on the acquisition of Trace Analytics, Inc. | ||||||||||||||||||||
| Goodwill (provisional) | ||||||||||||||||||||
| Other asset | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Due to related party | ||||||||||||||||||||
| Note Payable | ||||||||||||||||||||
| Convertible note payable - related party | ||||||||||||||||||||
| Convertible note payable - unrelated parties, net of debt discount of $153,170 at December 31, 2019 | ||||||||||||||||||||
| Convertible note payable to related party net of debt discount of $5,088 at June 30, 2019 | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Common stock; $0.00001 par value; 200,000,000 shares authorized: 14,100,956 issued and outstanding at December 31, 2019 (unaudited) and 13,397,110 at March 31, 2019 | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Common stock subscribed | ||||||||||||||||||||
| Common stock to be issued, 192,390 and 150,000 shares at December 31, 2017 (unaudited) and March 31, 2017, respectively | ||||||||||||||||||||
| Common stock to be issued, 200,000 and 150,000 shares at March 31, 2018 and 2017, respectively | ||||||||||||||||||||
| Common stock to be issued, 408,805 and 263,000 shares at March 31, 2019 and 2018, respectively | ||||||||||||||||||||
| Common stock to be issued, 808,805 shares at December 31, 2019 (unaudited) and 408,805 shares at March 31, 2019 | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Applied BioSciences Corp. Stockholders' Equity | ||||||||||||||||||||
| Non-controlling equity | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
